妇科恶性生殖细胞肿瘤的诊治与研究进展  

Treatment and research of gynecologic malignant germ cell tumors

作　　者：杨佳欣[1] 沈铿[1] 曹冬焱[1] 李舒[1] 向阳[1] YANG JiaXin;SHEN Keng;CAO DongYan;LI Shu;XIANG Yang(Department of Gynecological Oncology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences&Peking Union Medical College,Beijing 100730,China)

机构地区：[1]中国医学科学院&北京协和医学院,北京协和医院妇科肿瘤中心,北京100730

出　　处：《中国科学：生命科学》2021年第8期1007-1016,共10页Scientia Sinica(Vitae)

摘　　要：恶性生殖细胞肿瘤是一类来源于原始生殖细胞的罕见恶性肿瘤,该肿瘤发病年龄轻,主要呈现2个峰值,即0~4岁的幼女阶段和青春期至年轻女性阶段.该肿瘤普遍对化疗敏感.其治疗目标是,追求肿瘤治愈的同时,尽量保留年轻女性的生育功能,降低化疗毒副反应,提高生存质量.近年来,国内外临床和基础研究主要聚焦于根据危险因素对患者进行分层管理及精细化治疗、监测和降低化疗毒副反应、对晚期和复发耐药患者的治疗及耐药机制研究.本文就妇科恶性生殖细胞肿瘤的诊治与研究进展进行综述.Malignant germ cell tumors(MGCT)are rare malignant tumors derived from primordial germ cells.Incidence data show two distinct peaks in MGCT incidence,one in young children aged 0–4 and another extending from the onset of puberty through young adulthood.Generally,MGCT are sensitive to chemotherapy.The goal of treatment is to preserve the fertility function of young women as much as possible while pursuing tumor cure,monitor and reduce therapy-related toxicity,and improve the quality of life.In recent years,clinical and basic research has mainly focused on risk stratifying in MGCT patients,monitoring and reducing side effects of chemotherapy,managing patients with advanced and relapsed diseases,and exploring treatment and mechanisms of drug resistance.This article reviews the diagnosis,treatment and research progress of gynecologic malignant germ cell tumors.

关 键 词：妇科恶性生殖细胞 肿瘤手术 化疗 复发耐药 基础研究 

分 类 号：R737.3[医药卫生—肿瘤]